Zoetis Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZTS research report →
About the company
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses.
- CEO
- Kristin C. Peck
- IPO
- 2013
- Employees
- 13,800
- HQ
- Parsippany, NJ, US
Price Chart
- Market Cap
- $31.36B
- P/E
- 12.38
- P/S
- 3.30
- P/B
- 9.77
- EV/EBITDA
- 9.59
- Div Yield
- 2.75%
- Gross Margin
- 70.75%
- Op Margin
- 37.57%
- Net Margin
- 27.79%
- ROE
- 62.41%
- ROIC
- 21.79%
- Revenue
- $9.47B · 2.28%
- Net Income
- $2.67B · 7.52%
- EPS
- $6.03 · 10.24%
- Op Income
- $3.60B
- FCF YoY
- -0.65%
- 52W High
- $161.77
- 52W Low
- $71.47
- 50D MA
- $86.24
- 200D MA
- $117.33
- Beta
- 0.74
- Avg Volume
- 6.87M
Get TickerSpark's AI analysis on ZTS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | Stetter Mark | other | 317.622 |
| Jun 15, 26 | Nayak Abhay U | other | 0 |
| Jun 15, 26 | Nayak Abhay U | other | 253.088 |
| Jun 15, 26 | Nayak Abhay U | other | 4,423 |
| Jun 15, 26 | Nayak Abhay U | other | 3,590 |
| Jun 15, 26 | Nayak Abhay U | other | 2,830 |
| Jun 15, 26 | Nayak Abhay U | other | 3,314 |
| Jun 15, 26 | Nayak Abhay U | other | 8,106 |
| Jun 15, 26 | Nayak Abhay U | other | 1,508.773 |
| Jun 10, 26 | MCCALLISTER MICHAEL B | other | 1,209 |
Our ZTS coverage
Recent articles, reports, and earnings notes.
Zoetis (ZTS): Growth Reset, Still a Premium Franchise
Zoetis remains a high-quality animal health leader, but 2026 guidance cuts and softer U.S. companion-animal demand temper the near-term setup. The stock looks like a disciplined Buy with a fair value of $132.
Zoetis Inc. (ZTS) falls 13% after weak Q1 earnings
Zoetis Inc. (ZTS) falls sharply after reporting Q1 2026 results that missed expectations and came with softer full-year guidance. The selloff reflects weaker U.S. revenue, a profit miss, and a market reset for the animal-health leader.
Want a deeper read on ZTS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.